A securities fraud class action lawsuit has been filed against Insulet Corporation on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet made misleading statements by failing to disclose defective manufacturing controls and procedures, which created a heightened risk of product safety violations. On March 12, 2026, the company announced a voluntary Medical Device Correction for certain Omnipod 5 Pods, causing shares to fall 7% from $236.07 to $219.84. Then on May 26, 2026, another correction was disclosed for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery, leading to a 5% drop from $153.80 to $146.01. Investors have until August 31, 2026 to seek lead plaintiff appointment through Kirby McInerney LLP.
Insulet CorporationSecurities fraud lawsuit and product corrections for manufacturing defects causing share price drops